* Harrow Health Inc HROW.OQ HROW.O is expected to show a
rise
in quarterly revenue when it reports results on May 11.
* The Nashville Tennessee-based company is expected to
report a
13.7% increase in revenue to $25.146 million from $22.12 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Harrow Health Inc
is for
a loss of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Harrow
Health Inc
is $32.1, above its last closing price of $28.08.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.15 -0.12 0.04 Beat 134.3
Sep. 30 2022 -0.01 0.00 -0.24 Missed -9,500
Jun. 30 2022 -0.03 -0.01 -0.23 Missed -3,348
.3
Mar. 31 2022 -0.03 -0.03 0.03 Beat 185.7
Dec. -0.04 -0.04 -0.27 Missed -535.3
31 2021
Sep. 30 2021 -0.02 -0.02 -0.31 Missed -1,140
Jun. 30 2021 -0.03 -0.03 -0.09 Missed -200
Mar. 31 2021 -0.04 -0.03 0.01 Beat 128.6
This summary was machine generated May 10 at 01:48 GMT. All
figures in US dollars unless otherwise stated